Funding Opportunity RFA-CA-21-029 from the NIH Guide for Grants and Contracts. Informed by stakeholder input and a scan of the existing clinical and research landscape, the purpose of this initiative is to fund three research centers that can advance a national cancer-related telehealth research agenda in a rapidly changing healthcare, policy, and communication environment. Each center will support one signature project: a large pragmatic trial with the potential to generate findings with broad applicability to clinical practice and heterogenous patient populations. This collective of research centers will also support the infrastructure needed for designing innovative pilot studies on emerging issues in telehealth and cancer. The work of these centers is expected to foster the development, evaluation, and dissemination of innovative forms of telehealth with the potential to advance the delivery of cancer-related care as evidenced by improvements in quality of life and clinical outcomes, patient-physician communication, health equity, and/or access to quality care.

Funding Opportunity RFA-DA-22-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications from small business concerns (SBCs) to develop Artificial Intelligence (AI)-related technologies for drug discovery and drug development for Substance Use Disorders (SUD), excluding alcohol use disorder

Funding Opportunity RFA-DA-22-019 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications from small business concerns (SBCs) to develop Artificial Intelligence (AI)-related technologies for drug discovery and drug development for Substance Use Disorders (SUD), excluding alcohol use disorder

Funding Opportunity RFA-MH-21-180 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support establishment of facilities at minority-serving institutions (MSIs) and Institutional Development Award (IDeA)-eligible institutions for scaled production and distribution of brain cell type-specific access and manipulation reagents. Reagents will be initially developed in pilot resource projects for brain cell type-specific access and manipulation across vertebrate species from the BRAIN Initiative Armamentarium project. Awardees under this FOA will work with the other Armamentarium awardees to manufacture and distribute the resources for use throughout the neuroscience community. It is envisioned that the awardees will work both with the Armamentarium community as well as with the neuroscience research community to optimize the use of new reagents. The types of reagents to be produced and distributed could include but are not limited to viral vectors, nucleic acid constructs, and nanoparticles designed for selective access to and manipulation of brain cell types. Such reagents will enable neuroscientists to probe circuit function with high precision in experimental animals and ex vivo human tissue and cells. Facilities are needed to contribute to the production and distribution of BRAIN Initiative Armamentarium project reagents broadly to neuroscience users.

Funding Opportunity RFA-AI-21-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that use innovative technology to conduct epidemiologic studies of large cohorts of U.S. populations at high risk of HIV: men who have sex with men (MSM), people who inject drugs (PWID), and transgender women and men, focusing especially on the minority and age groups at highest risk of HIV transmissions. The major goal is to support investigators who will use innovative electronic methods to recruit and retain large samples of persons at high risk of HIV, comparing those who become HIV-positive to those who do not, and optionally to develop and test digitally-delivered interventions that promote HIV risk reduction to reduce HIV-incidence.

Funding Opportunity RFA-AI-21-013 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support multi-disciplinary, Program Project applications aimed at understanding changes in the HIV reservoir over time in different cell types and tissues. A better understanding of the mechanisms that govern HIV reservoir dynamics over time is essential to inform the development of strategies to cure HIV or control viral infection to overcome the need for life-long antiretroviral therapy.

Funding Opportunity RFA-RM-21-015 from the NIH Guide for Grants and Contracts. The NIH Directors Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative and potentially transformative research towards the ultimate goal of enhancing human health. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigators research program or elsewhere. The NIH Directors Pioneer Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.

Funding Opportunity PAR-21-213 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance research on the impact of SARS-CoV-2 and associated mitigation efforts on individual, family, and community behavior and on how subsequent economic disruption affects health-related outcomes, with close attention to underserved and vulnerable populations.

Funding Opportunity RFA-DK-21-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective cell replacement therapies for type 1 diabetes (T1D). The purpose is to support research leading to the development and testing of novel and supportive technologies for the improvement of cell replacement interventions using novel biomaterials and devices for T1D treatment.

Notice NOT-AA-21-019 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-203 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Clinical and Translational Science Awards (CTSA) Program consortium-wide resource centers that will rapidly demonstrate and disseminate to the wider consortium innovative resources (to include capabilities) that have established impact at a local or national level. Applications for CTSA consortium-wide centers are expected to rapidly demonstrate and disseminate resources to advance clinical and translational science efforts. Only applications submitted in response to a Notice of Special Interest (NOSI) published by NCATS will be allowed to apply to this FOA.

Funding Opportunity PAR-21-207 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites R01 applications for ancillary studies that address psychological and interpersonal mechanisms driving adherence to behavior or lifestyle change relevant to the prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Successful applications will seek to identify malleable, mechanistic, psychological, or interpersonal targets that if modified will strengthen adherence to, maintenance of, and continued/renewed engagement in behaviors that may promote cognitive health and prevent AD/ADRD.

Funding Opportunity RFA-AG-22-016 from the NIH Guide for Grants and Contracts. The ultimate goal of this R61/R33 Funding Opportunity Announcement (FOA) is to identify meaningful (e.g., causal), modifiable factors that promote adherence to lifestyle changes or to other (e.g., cognitive training) behaviors that hold potential for prevention of cognitive decline, MCI, and AD/ADRD. Specifically, this will be done by conducting research to understand how, why, and for whom particular features of behavior change interventions engage specific psychological or interpersonal processes that promote maintenance of (adherence to) health behaviors. Applications in response to this FOA (and to the companion R01 FOA) should be framed within the NIH Stage Model. Additionally, this FOA supports new early- to late- stage (including Stages I-IV) research projects. Projects should create, refine, and test interventions that target individual- and interpersonal-level mechanisms of adherence to healthful behavioral patterns and to other prevention approaches for cognitive decline, MCI, and AD/ADRD (e.g., cognitive training). Additionally, this FOA supports studies that integrate basic science questions of how psychological and interpersonal targets (i.e., processes we can manipulate) and mechanisms may inform the design and development of effective, efficient, and personalized approaches to promote adherence to behavior change for the prevention of AD/ADRD and to help optimize healthy aging over the life course.

Funding Opportunity RFA-HD-21-033 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support interdisciplinary community-engaged research designed to reduce or eliminate infections and sepsis as causes of pregnancy-related or associated morbidity and mortality (PRAMM) in regions of the United States with high rates of maternal mortality. This FOA is to support research primarily focused on PRAMM health disparities in areas with highest maternal morbidity and mortality.

Notice NOT-OD-21-087 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-21-020 from the NIH Guide for Grants and Contracts. The purpose of this specific FOA is to solicit applications to build a set of Cutting Edge Informatics Tools (CEITs) that will augment the capability of the KMC as well as the broader IDG Consortium in the following ways: (1) by developing and deploying tools to enhance the community's ability to process, analyze, and visualize IDG data, (2) to prioritize new data resources and methods to be incorporated into Pharos https://pharos.nih.gov/idg/index that will strengthen predictions about physiological and disease associations around the understudied proteins, and (3) by developing methods to prioritize understudied IDG families (non-olfactory GPCRs, protein kinases, and ion channels) for deeper study using experimental assays both within the IDG pipeline or by the larger community.

Funding Opportunity PAR-21-188 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences

Funding Opportunity RFA-DK-21-501 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites one application from the Program Director/Principal Investigator (PD/PI) of the current Data Coordinating Center (DCC) for Type 1 Diabetes Acute Pancreatitis Consortium (T1DAPC). This 5-year longitudinal observational clinical study was originally funded in September 2020 and is currently in its planning phase. It will conduct a prospective longitudinal observational study of the occurrence of new onset diabetes during an acute pancreatitis (AP) episode or subsequently, with an emphasis on type 1 diabetes (T1D). The study is designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of diabetes after AP. The DCC is involved in coordination and study design, including data and biosample acquisition and management and is responsible for distribution of funding to the clinical centers for participant costs. This supplement provides funding for the T1DAPC DCC to support longitudinal Magnetic Resonance Imaging (MRI) and other types of biomarker studies of enrolled participants.

Notice NOT-LM-21-006 from the NIH Guide for Grants and Contracts

Notice NOT-AA-21-012 from the NIH Guide for Grants and Contracts